

Raquel Duran

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5148050/raquel-duran-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

28
papers

1,191
citations

16
h-index

30
g-index

30
ext. papers

1,455
ext. citations

5.1
avg, IF

3.32
L-index

#	Paper	IF	Citations
28	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. <i>Movement Disorders</i> , 2019 , 34, 1851-1863	7.863	18
27	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 460-468	7	40
26	Asymmetrical response of aminopeptidase A in the medial prefrontal cortex and striatum of 6-OHDA-unilaterally-lesioned Wistar Kyoto and spontaneously hypertensive rats. <i>Pharmacology Biochemistry and Behavior</i> , 2019 , 182, 12-21	3.9	4
25	Bilateral distribution of enkephalinase activity in the medial prefrontal cortex differs between WKY and SHR rats unilaterally lesioned with 6-hydroxydopamine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017 , 75, 213-218	5.5	9
24	Structural genomic variations and Parkinson's disease. <i>Minerva Medica</i> , 2017 , 108, 438-447	2.2	8
23	Genome-wide assessment of Parkinson's disease in a Southern Spanish population. <i>Neurobiology of Aging</i> , 2016 , 45, 213.e3-213.e9	5.6	23
22	Analysis of the genetic variability in Parkinson's disease from Southern Spain. <i>Neurobiology of Aging</i> , 2016 , 37, 210.e1-210.e5	5.6	16
21	An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies. <i>Journal of Clinical Rheumatology</i> , 2015 , 21, 115-9	1.1	18
20	The glucocerebrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. <i>Movement Disorders</i> , 2013 , 28, 232-236	7	86
19	Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. <i>Brain</i> , 2013 , 136, 392-9	11.2	201
18	Genotype and phenotype in Parkinson's disease: lessons in heterogeneity from deep brain stimulation. <i>Movement Disorders</i> , 2013 , 28, 1370-5	7	55
17	A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. <i>JAMA Neurology</i> , 2013 , 70, 727-35	17.2	285
16	Hyposmia and cognitive impairment in Gaucher disease patients and carriers. <i>Movement Disorders</i> , 2012 , 27, 526-32	7	80
15	Novel pathogenic mutations in the glucocerebrosidase locus. <i>Molecular Genetics and Metabolism</i> , 2012 , 106, 495-7	3.7	3
14	A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 853-4	5.5	76
13	Oxidative stress and aminopeptidases in Parkinson's disease patients with and without treatment. <i>Neurodegenerative Diseases</i> , 2011 , 8, 109-16	2.3	6
12	Lateralized response of oxytocinase activity in the medial prefrontal cortex of a unilateral rat model of Parkinson's disease. <i>Behavioural Brain Research</i> , 2010 , 213, 328-31	3.4	8

11	Oxidative stress and plasma aminopeptidase activity in Huntington's disease. <i>Journal of Neural Transmission</i> , 2010 , 117, 325-32	4-3	25
10	Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment. <i>Movement Disorders</i> , 2010 , 25, 489-93	7	73
9	Stress influences brain enkephalinase, oxytocinase and angiotensinase activities: a new hypothesis. <i>Neuropsychobiology</i> , 2009 , 59, 184-9	4	22
8	Asymmetrical response of aminopeptidase A and nitric oxide in plasma of normotensive and hypertensive rats with experimental hemiparkinsonism. <i>Neuropharmacology</i> , 2009 , 56, 573-9	5-5	21
7	Role of aminopeptidases in the neuroendocrine control of blood pressure in experimental animals. <i>Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2008 , 55, 402-8		1
6	Atrial angiotensinase activity in hypothyroid, euthyroid, and hyperthyroid rats. <i>Journal of Cardiovascular Pharmacology</i> , 2006 , 48, 117-20	3-1	4
5	Plasma aminopeptidase activities in Parkinson's disease. <i>Hormone and Metabolic Research</i> , 2006 , 38, 758-60	5-0	6
4	Brain aminopeptidases and hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006 , 7, 129-34	3	33
3	Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the L-dopa. <i>Journal of the Neurological Sciences</i> , 2006 , 240, 31-6	3-2	54
2	Aminopeptidase activity in the nigrostriatal system and prefrontal cortex of rats with experimental hemiparkinsonism. <i>Hormone and Metabolic Research</i> , 2005 , 37, 53-5	3-1	4
1	Plasma aminopeptidase activities in rats after left and right intrastriatal administration of 6-hydroxydopamine. <i>Neuroendocrinology</i> , 2004 , 80, 219-24	5-6	12